Preliminary Programme

Drug discovery and development case study 3
E. ARNOLD, Rutgers University, Piscataway, NJ, USA

Historical perspective
T.L. BLUNDELL, Cambridge University, UK

Data integration & pharmacology
A. BRADLEY, Exscientia, Oxford, UK

Developability
R. BUICK, Fusionantibodies, Belfast, IR

• Bioinformatic
• Intro to biologics
C. DEANE, Oxford University, UK

• High-throughput and automation
• Measuring binding
F. von DELFT, Diamond Light Source, Oxford, UK

Rational design
S. J. FLEISHMAN, Weizmann Institute, IL

Drug discovery and development case study
S. JACOB, Novartis, CH

Advancing drug discovery
A. KOTECHA, Thermo Fisher Scientific

General crystallography
C. LESBURG, Odyssey Therapeutics, Cambridge, MA, USA

Drug discovery and development case study 2
G. McGAUGHEY, Vertex, Boston, MA, USA

Docking / Free energy calculation / MD
S. RINIKER, ETH, Zurich, CH

CryoEM in drug discovery
G. SCAPIN, NanoImaging Services, Woburn, MA, USA

Rationalising biomolecular interactions
R. WADE, HITS and Heidelberg University, DE

Small-molecule chimeras
J. WILLIAMS, City of Hope, Duarte, CA, USA